Skip to main content
Premium Trial:

Request an Annual Quote

Human Longevity Suit Against JCVI Dismissed

A California judge has dismissed a lawsuit brought by Human Longevity against the J. Craig Venter Institute, as GenomeWeb has reported.

This summer, Human Longevity sued JCVI, alleging that Craig Venter, the founder both of Human Longevity and JCVI, stole trade secrets. Venter launched Human Longevity in 2014 and served as its CEO until January 2018, though he then returned for a short stint as interim CEO in November 2017. Venter announced his retirement from Human Longevity and return to JCVI in May of this year.

In its suit, Human Longevity alleged that when Venter left, he took a company laptop containing trade secrets that he then gave to JCVI. Stat News adds that the laptop allegedly contained the names and contact information of Human Longevity’s clients and prospective clients, and that Human Longevity alleged that Venter tried to poach employees and investors.

However, the US District Court of the Southern District of California dismissed the suit this week, saying that Human Longevity's suit didn’t meet the legal threshold for the misappropriation of trade secrets.

The Wall Street Journal reported earlier this month that Human Longevity has lost 80 percent of its valuation, and is now valued at $310 million, down from $1.6 billion.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.